Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

NCT ID: NCT05893498

Last Updated: 2025-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

1924 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-21

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ALL-RISE is a prospective, randomized, multi-center, controlled post-market study. The ALL-RISE study is designed to test whether FFRangio-guided treatment is non-inferior to conventional pressure wire-guided treatment in patients with coronary artery disease being evaluated for percutaneous coronary intervention (PCI) with respect to major adverse cardiac events (MACE) at one year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Percutaneous Coronary Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FFRangio

FFRangio guided revascularization

Group Type EXPERIMENTAL

FFRangio

Intervention Type DEVICE

A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.

Pressure wire

Pressure wire-based guided revascularization (FFR or NHPR)

Group Type ACTIVE_COMPARATOR

FFR or NHPR

Intervention Type DEVICE

Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FFRangio

A 3D image-base software device (CathWorks, Ltd, Kfar Saba, Israel) using three (3) angiographic views to provide a quantitative analysis of the functional significance of coronary lesions.

Intervention Type DEVICE

FFR or NHPR

Using an invasive pressure-wire to assess functional significance of coronary lesions either under hyperemic conditions (FFR) or utilizing Non-hyperemic pressure ratios (NHPR).

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FFR, iFR RFR, dPR, Pd/Pa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Adult patient ( ≥18 years old) presenting with CCS or NSTEACS with one or more study lesion(s) deemed appropriate (diameter stenosis 50-90%) for both pressure-wire and FFRangio physiologic assessment.

Exclusion Criteria

1. Subject with ST-elevation (MI (STEMI) within 72 hours at time of study enrollment
2. Prior coronary artery bypass graft (CABG) with patent grafts to the study vessel(s)
3. Patients undergoing coronary physiologic assessment where one possible outcome is referral for CABG
4. The study vessel supplies a significant nonviable territory (e.g., prior transmural MI)
5. Severe left sided valvular heart disease
6. Most recent documented LVEF ≤30%
7. Women who are pregnant or breastfeeding (women of childbearing potential are required to have negative pregnancy test within 1 week of index procedure)
8. Patients with life expectancy \<1 year life as estimated by treating physician.
9. Subjects enrolled in other ongoing non-registry clinical studies that would impact conduct or outcomes of this study (registries and long-term follow-up of other studies are allowed)
10. Subjects who have undergone angiographic or wire-based coronary physiological assessment for 1 or more potential study lesions within 30 days of enrollment.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cardiovascular Research Foundation, New York

OTHER

Sponsor Role collaborator

CathWorks Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ajay J Kirtane, MD, SM

Role: STUDY_CHAIR

NewYork-Presbyterian/Columbia University Irving Medical Center

William F Fearon, MD

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Allen Jeremias, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

St. Francis Hospital & Heart Center

Martin B Leon, MD

Role: STUDY_CHAIR

NewYork-Presbyterian/Columbia University Irving Medical Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California San Diego Health

La Jolla, California, United States

Site Status

VA- Long Beach Healthcare

Long Beach, California, United States

Site Status

Keck Medicine of USC

Los Angeles, California, United States

Site Status

UCLA Medical Center

Los Angeles, California, United States

Site Status

Stanford University

Palo Alto, California, United States

Site Status

VA - Palo Alto Healthcare

Palo Alto, California, United States

Site Status

Kaiser Permanente San Francisco

San Francisco, California, United States

Site Status

St. Joesph's Medical Center

Stockton, California, United States

Site Status

MedStar Health Research Institute

Washington D.C., District of Columbia, United States

Site Status

HCA Florida JFK Hospital

Atlantis, Florida, United States

Site Status

Cardiac & Vascular Institute

Gainesville, Florida, United States

Site Status

HCA Florida Largo Hospital

Largo, Florida, United States

Site Status

HCA Florida Northside Hospital

St. Petersburg, Florida, United States

Site Status

Tallahassee Research Institute

Tallahassee, Florida, United States

Site Status

Archbold Hospital

Thomasville, Georgia, United States

Site Status

Carle Foundation Hospital

Urbana, Illinois, United States

Site Status

Ascension Via Christi St. Francis

Wichita, Kansas, United States

Site Status

Kansas Heart Hospital

Wichita, Kansas, United States

Site Status

St. Elizabeth Healthcare

Edgewood, Kentucky, United States

Site Status

Medstar Union Memorial Hospital

Baltimore, Maryland, United States

Site Status

TidalHealth, INC

Salisbury, Maryland, United States

Site Status

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Site Status

Ascension St. John Hospital

Detroit, Michigan, United States

Site Status

Metropolitan Heart Vascular Institute

Coon Rapids, Minnesota, United States

Site Status

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, United States

Site Status

Cardiac Associates Research

Tupelo, Mississippi, United States

Site Status

Mountainside Medical Center

Montclair, New Jersey, United States

Site Status

Morristown Medical Center

Morristown, New Jersey, United States

Site Status

The Valley Hospital

Ridgewood, New Jersey, United States

Site Status

New York Presbyterian Methodist Hospital

Brooklyn, New York, United States

Site Status

NYU Langone Health

New York, New York, United States

Site Status

Columbia University Medical Center / New York Presbyterian Hospital

New York, New York, United States

Site Status

New York Presbyterian / Weill Cornell Medical Center

New York, New York, United States

Site Status

Northwell Health (Lenox Hill, North Shore, South Shore, Huntington, Staten Island))

New York, New York, United States

Site Status

St. Francis Hospital and Heart Center

Roslyn, New York, United States

Site Status

Ellis Hospital

Schenectady, New York, United States

Site Status

The Christ Hospital

Cincinnati, Ohio, United States

Site Status

Mount Carmel Health System

Columbus, Ohio, United States

Site Status

Lehigh Valley Health

Allentown, Pennsylvania, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Baylor Scott & White The Heart Hospital - Plano

Plano, Texas, United States

Site Status

HCA Methodist Healthcare of San Antonio

San Antonio, Texas, United States

Site Status

Inova Fairfax Hospital

Fairfax, Virginia, United States

Site Status

Rabin Medical Centre

Petah Tikva, , Israel

Site Status

Gifu Heart Center

Gifu, , Japan

Site Status

Kobe University

Kobe, , Japan

Site Status

Mie University Hospital

Osaka, , Japan

Site Status

Sakakibara Heart Institute

Tokyo, , Japan

Site Status

Hopitaux Universitaires Geneve (HUG)

Geneva, , Switzerland

Site Status

centre hospitalier universitaire vaudois (CHUV)

Lausanne, , Switzerland

Site Status

Imperial College Healthcare

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Israel Japan Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Redfors B, Madhavan MV, Kirtane AJ, Fearon WF, Yeh RW, Cohen DJ, Al-Lamee R, Jeremias A, Witberg G, Sharma RP, Popma A, Kaki A, Froimovich A, Leon MB. FFRangio-guided versus pressure wire-guided PCI: design and rationale of the multicentre, randomised ALL-RISE trial. EuroIntervention. 2025 Aug 18;21(16):961-969. doi: 10.4244/EIJ-D-25-00200.

Reference Type DERIVED
PMID: 40828315 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CathWorks CWX-08

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PRESSUREwire Study
NCT02935088 COMPLETED
INSIGHTFUL-FFR Clinical Trial
NCT05437900 RECRUITING PHASE4